# S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma

> **NCT00238212** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (estimated)

## Conditions studied

- Adenocarcinoma of the Extrahepatic Bile Duct
- Adenocarcinoma of the Gallbladder
- Adenocarcinoma With Squamous Metaplasia of the Gallbladder
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Cholangiocarcinoma of the Gallbladder
- Recurrent Extrahepatic Bile Duct Cancer
- Recurrent Gallbladder Cancer
- Squamous Cell Carcinoma of the Gallbladder
- Unresectable Extrahepatic Bile Duct Cancer
- Unresectable Gallbladder Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00238212
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00238212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00238212, "S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00238212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*